Riskpilot← Back to searchSign inGet full accessMiMa Pharma AB
ABActiveOrg 5592540123Åkervägen 12Business and other management consultancy activities · NACE 7020Est. 20200 employees
Revenue 2025
SEK 209K
+481% vs 2024
EBITDA margin
68.1%
+4551% vs 2024
Equity ratio
66.9%
Financial strength
Net profit 2025
SEK 117K
+4060% vs 2024
| Revenue | SEK 209K | +481% |
| EBITDA | SEK 142K | +4551% |
| Net profit | SEK 117K | +4060% |
| Total assets | SEK 257K | +228% |
| Equity | SEK 172K | +211% |
| Employees | 0 | — |
Legal name
MiMa Pharma AB
Org number
5592540123
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
29 april 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Affärsutveckling, affärsplanering, affärsrådgivning, affärsstrategi, konsultverksamhet. Handel med värdepapper. Konsultverksamhet främst med inriktning inom LifeScience samt medicintekniska produkter.
Address
Åkervägen 12
Email
m.nordberg@syntamera.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 115 | 41 | 65 | 36 | 209 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 76 | −16 | −9 | −3 | 142 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 76 | −16 | −9 | −3 | 142 |
| Net financials | — | — | −0 | 0 | 0 |
| Profit before tax | 76 | −16 | −9 | −3 | 142 |
| Tax | −16 | — | — | — | −26 |
| Net profit | 60 | −16 | −9 | −3 | 117 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 130 | 96 | 71 | 78 | 257 |
| Equity | 83 | 67 | 58 | 55 | 172 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 46 | 28 | 12 | 23 | 85 |
| Total debt | 46 | 28 | 12 | 23 | 85 |
EBITDA margin
68.1%
This company
15.8%
Market median
+331% vs market
20212025
Equity ratio
66.9%
This company
38.2%
Market median
+75% vs market
20212025
Return on equity
67.9%
This company
18.4%
Market median
+269% vs market
20212025
Net profit margin
55.9%
This company
8.1%
Market median
+590% vs market
20212025
Asset turnover
0.81×
This company
1.12×
Market median
+28% vs market
20212025
Debt / equity
0.49×
This company
0.62×
Market median
+21% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BG Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MiMa Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Gunnar Mikael Nordberg | Chief Executive Officer | 0 companies |
| Cecilia Kristina Nordberg | Deputy Board Member | 0 companies |
| Malin Kristina Graffner Nordberg | Chairman | 0 companies |
| Nils Albert Nordberg | Deputy Board Member | 0 companies |